The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism

Transplantation

Volumn 91, Issue 5, 2011, Pages 560-565

  Schwarz, Anke ^a   Merkel, Saskia ^a   Leitolf, Holger ^a   Haller, Hermann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cinacalcet; Parathyroid hormone; Renal function; Renal transplantation

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CINACALCET; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; STEROID; TACROLIMUS; TELOPEPTIDE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERPARATHYROIDISM; KIDNEY BIOPSY; KIDNEY CALCIFICATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

AGED; BIOPSY; BONE AND BONES; CALCIUM; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HOMEOSTASIS; HUMANS; HYPERPARATHYROIDISM; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NAPHTHALENES; NEPHROCALCINOSIS; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES;

EID: 79952190801     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182079431     Document Type: Article

References (54)

1. David DS, Sakai S, Brennan BL, et al. Hypercalcemia after renal transplantation. Long-term follow-up data. N Engl J Med 1973; 289: 398.
2. Cundy T, Kanis JA, Heynen G, et al. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 1983; 52: 67.
3. D'Alessandro AM, Melzer JS, Pirsch JD, et al. Tertiary hyperparathyroidism after renal transplantation: Operative indications. Surgery 1989; 106: 1049; discussion 1055.
4. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13: 551.
5. Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant 2004; 19: 1281.
6. Lee PP, Schiffmann L, Offermann G, et al. Effects of parathyroidectomy on renal allograft survival. Kidney Blood Press Res 2004; 27: 191.
7. Rostaing L, Moreau-Gaudry X, Baron E, et al. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1997; 47: 248.
8. Evenepoel P, Claes K, Kuypers D, et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: A single centre study. Nephrol Dial Transplant 2005; 20: 1714.
9. Garcia A, Mazuecos A, Garcia T, et al. Effect of parathyroidectomy on renal graft function. Transplant Proc 2005; 37: 1459.
10. Triponez F, Dosseh D, Hazzan M, et al. Subtotal parathyroidectomy with thymectomy for autonomous hyperparathyroidism after renal transplantation. Br J Surg 2005; 92: 1282.
11. Schwarz A, Rustien G, Merkel S, et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007; 22: 584.
12. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95: 4040.
13. Valle C, Rodriguez M, Santamaria R, et al. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol 2008; 19: 2430.
14. Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017.
15. Block GA, Martin KJ, De Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516.
16. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800.
17. Messa P, Macario F, Yaqoob M, et al. The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36.
18. Malluche HH, Monier-Faugere MC, Wang G, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008; 69: 269.
19. Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005; 67: 341.
20. Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: Causes and clinical implications. Am J Transplant 2005; 5: 1934.
21. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141.
22. Borchhardt K, Sulzbacher I, Benesch T, et al. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007; 7: 2515.
23. Borchhardt KA, Diarra D, Sulzbacher I, et al. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol 2010; 31: 482.
24. Yajima A, Inaba M, Tominaga Y, et al. Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 2008; 74: 775.
25. Kruse AE, Eisenberger U, Frey FJ, et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311.
26. Kruse AE, Eisenberger U, Frey FJ, et al. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007; 22: 2362.
27. Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1315.
28. Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007; 22: 577.
29. Apostolou T, Kollia K, Damianou L, et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplant Proc 2006; 38: 3514.
30. Srinivas TR, Schold JD, Womer K, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin Am J Nephrol 2006; 1: 323.
31. Leca N, Laftavi M, Gundroo A, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6: 2391.
32. Szwarc I, Argiles A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82: 675.
33. Bergua C, Torregrosa JV, Cofan F, et al. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc 2007; 39: 2254.
34. El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546.
35. Carrasco FR, Pérez-Flores I, Calvo N, et al. Treatment of persistent hyperparathyroidism in renal transplant patients with cinacalcet improves control of blood pressure. Transplant Proc 2009; 41: 2385.
36. Gomez Marques G, Obrador Mulet A, Vilar Gimeno A, et al. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation. Transplant Proc 2009; 41: 2139.
37. Lopez V, Toledo R, Sola E, et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc 2009; 41: 2394.
38. Toro Prieto FJ, Bernal Blanco G, Navarro Garcia M, et al. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant Proc 2009; 41: 2144.
39. Borchhardt KA, Heinzl H, Mayerwoger E, et al. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008; 86: 919.
40. Serra AL, Braun SC, Starke A, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 2008; 8: 803.
41. Kamar N, Gennero I, Spataru L, et al. Pharmacodynamic effects of cinacalcet after kidney transplantation: Once- versus twice-daily dose. Nephrol Dial Transplant 2008; 23: 3720.
42. Falck P, Vethe NT, Asberg A, et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008; 23: 1048.
43. Ellison DH, McCarron DA. Structural prerequisites for the hypotensive action of parathyroid hormone. Am J Physiol 1984; 246(5 pt 2): F551.
44. Trizna W, Edwards RM. Relaxation of renal arterioles by parathyroid hormone and parathyroid hormone-related protein. Pharmacology 1991; 42: 91.
45. Massfelder T, Parekh N, Endlich K, et al. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized rat. Br J Pharmacol 1996; 118: 1995.
46. Jespersen B, Randlov A, Abrahamsen J, et al. Effects of PTH(1-34) on blood pressure, renal function, and hormones in essential hypertension: The altered pattern of reactivity may counteract raised blood pressure. Am J Hypertens 1997; 10(12 pt 1): 1356.
47. Ogata H, Ritz E, Odoni G, et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003; 14: 959.
48. Henley C, Colloton M, Cattley RC, et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1370.
49. Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and design overview. Clin J Am Soc Nephrol 2007; 2: 898.
50. Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100: 2977.
51. Wada M, Nagano N, Furuya Y, et al. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57: 50.
52. Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467.
53. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009; 24: 982.
54. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.